Deep learning predicts cardiovascular disease risks from lung cancer screening low dose computed tomography.
Hanqing ChaoHongming ShanFatemeh HomayouniehRamandeep SinghRuhani Doda KheraHengtao GuoTimothy SuG E WangMannudeep K KalraPingkun YanPublished in: Nature communications (2021)
Cancer patients have a higher risk of cardiovascular disease (CVD) mortality than the general population. Low dose computed tomography (LDCT) for lung cancer screening offers an opportunity for simultaneous CVD risk estimation in at-risk patients. Our deep learning CVD risk prediction model, trained with 30,286 LDCTs from the National Lung Cancer Screening Trial, achieves an area under the curve (AUC) of 0.871 on a separate test set of 2,085 subjects and identifies patients with high CVD mortality risks (AUC of 0.768). We validate our model against ECG-gated cardiac CT based markers, including coronary artery calcification (CAC) score, CAD-RADS score, and MESA 10-year risk score from an independent dataset of 335 subjects. Our work shows that, in high-risk patients, deep learning can convert LDCT for lung cancer screening into a dual-screening quantitative tool for CVD risk estimation.
Keyphrases
- deep learning
- computed tomography
- low dose
- cardiovascular disease
- end stage renal disease
- coronary artery
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- type diabetes
- magnetic resonance imaging
- cardiovascular events
- artificial intelligence
- image quality
- coronary artery disease
- machine learning
- randomized controlled trial
- convolutional neural network
- study protocol
- heart rate
- open label
- patient reported outcomes
- mass spectrometry
- contrast enhanced
- pulmonary hypertension
- patient reported
- cardiovascular risk factors
- breast cancer risk